Skip to main content
Fig. 1 | BMC Immunology

Fig. 1

From: Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Fig. 1

Measurement of levels of adalimumab (ABP501/Humira®) and anti-adalimumab (Anti-ABP501/Anti-Humira®) in patients or spiked samples according to the Adalimumab standard curve. The coefficient of determination (R2) and the slope were calculated for the 3 different combinations. a Adalimumab correlation: ABP501-batch1 versus Humira® (R2 = 0.95; slope: 0.94) (A), ABP501-batch2 versus Humira® (R2 = 0.98; slope: 0.94) (B), ABP501-batch1 versus ABP501-batch2 (R2 = 0.94; slope: 0.95) (C). b Anti-adalimumab correlation: ABP501-batch1 versus Humira® (R2 = 0.98; slope: 1.05) (D), ABP501-batch2 versus Humira® (R2 = 0.93; slope: 1.04) (E), ABP501-batch1 versus ABP501-batch2 (R2 = 0.97; slope: 0.97) (F). All the quantifications were measured with the LISA-TRACKER Duo Adalimumab assay

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us